Stalevo(carbidopa/levodopa and entacapone): Ongoing Safety Review: Possible increased cardiovascular risk
Links shared publicly online about this topic.
- 937total visits
Stalevo(carbidopa/levodopa and entacapone): Ongoing Safety Review: Possible increased cardiovascular risk
fda.gov —
FDA evaluating clinical trial data that suggest patients taking drug may be at an increased risk for cardiovascular events compared to those taking carbidopa/levodopa
View full resource at fda.gov
Most Recently Shared on August 20, 2010 at 8:05 pm By:
#FDA Stalevo(carbidopa/levodopa and entacapone): Ongoing Safety Review: Possible increased cardiovascular risk http://t.co/FTVOYRm
FDA Alert: Stalevo(carbidopa/levodopa and entacapone): Ongoing Safety Review: Possible increased cardiovascular risk
drugs.com — “FDA Alert: Stalevo(carbidopa/levodopa and entacapone): Ongoing Safety Review: Possible increased cardiovascular risk” View full resource at drugs.com
Most Recently Shared on August 22, 2010 at 11:37 pm By:
FDA Alert - Ongoing Safety Review: Stalevo (carbidopa/levodopa and entacapone) - http://bit.ly/90MUk2
Advertisement
